442 related articles for article (PubMed ID: 9413216)
1. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
Fichtner I; Dehmel A; Naundorf H; Finke LH
Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD44 isoforms in human breast carcinoma xenografts is not influenced by the treatment of mice with cytostatics or (anti-)hormones.
Dehmel A; Becker M; Lemm M; Fichtner I
Anticancer Res; 1999; 19(3A):1977-87. PubMed ID: 10470143
[TBL] [Abstract][Full Text] [Related]
3. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
Reeder JA; Gotley DC; Walsh MD; Fawcett J; Antalis TM
Cancer Res; 1998 Aug; 58(16):3719-26. PubMed ID: 9721884
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.
Abetamann V; Kern HF; Elsässer HP
Clin Cancer Res; 1996 Sep; 2(9):1607-18. PubMed ID: 9816340
[TBL] [Abstract][Full Text] [Related]
5. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
[TBL] [Abstract][Full Text] [Related]
6. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
7. The influence of hormones on CD44 expression in endometrial and breast carcinomas.
Durst B; Sorg RV; Röder G; Betz B; Beckmann MW; Niederacher D; Bender HG; Dall P
Oncol Rep; 2001; 8(5):987-93. PubMed ID: 11496303
[TBL] [Abstract][Full Text] [Related]
8. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
Afify A; Purnell P; Nguyen L
Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
[TBL] [Abstract][Full Text] [Related]
9. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells.
Welsh CF; Zhu D; Bourguignon LY
J Cell Physiol; 1995 Sep; 164(3):605-12. PubMed ID: 7544357
[TBL] [Abstract][Full Text] [Related]
10. New CD44 splice variants associated with human breast cancers.
Iida N; Bourguignon LY
J Cell Physiol; 1995 Jan; 162(1):127-33. PubMed ID: 7529235
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
12. CD44 is expressed in hepatocellular carcinomas showing vascular invasion.
Mathew J; Hines JE; Obafunwa JO; Burr AW; Toole K; Burt AD
J Pathol; 1996 May; 179(1):74-9. PubMed ID: 8691349
[TBL] [Abstract][Full Text] [Related]
13. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ.
Kurebayashi J; McLeskey SW; Johnson MD; Lippman ME; Dickson RB; Kern FG
Cancer Res; 1993 May; 53(9):2178-87. PubMed ID: 8481921
[TBL] [Abstract][Full Text] [Related]
14. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis.
Urquidi V; Sloan D; Kawai K; Agarwal D; Woodman AC; Tarin D; Goodison S
Clin Cancer Res; 2002 Jan; 8(1):61-74. PubMed ID: 11801541
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.
Terpe HJ; Störkel S; Zimmer U; Anquez V; Fischer C; Pantel K; Günthert U
Am J Pathol; 1996 Feb; 148(2):453-63. PubMed ID: 8579108
[TBL] [Abstract][Full Text] [Related]
16. Splice variant expression of CD44 in patients with breast and ovarian cancer.
Sanchez Lockhart M; Hajos SE; Basilio FM; Mongini C; Alvarez E
Oncol Rep; 2001; 8(1):145-51. PubMed ID: 11115587
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck.
Herold-Mende C; Seiter S; Born AI; Patzelt E; Schupp M; Zöller J; Bosch FX; Zöller M
J Pathol; 1996 May; 179(1):66-73. PubMed ID: 8691348
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 splice variants in normal, dysplastic, and neoplastic cervical epithelium.
Woerner SM; Givehchian M; Dürst M; Schneider A; Costa S; Melsheimer P; Lacroix J; Zöller M; Doeberitz MK
Clin Cancer Res; 1995 Oct; 1(10):1125-32. PubMed ID: 9815903
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas.
Chuang CK; Liao SK
Anticancer Res; 2003; 23(6C):4635-9. PubMed ID: 14981907
[TBL] [Abstract][Full Text] [Related]
20. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
